{"entity":{"id":"nct05101070","kind":"trial","name":"S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors","aka":["aCCeleR8-001"],"tldr":"A phase 1/2 trial of Pembrolizumab and Bevacizumab in advanced solid tumours, run by Shionogi, now recruiting.","summary":"S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05101070 by Shionogi, with 282 participants planned, started 2022-05-30 and due to reach its primary completion in 2028-05-31. Interventions recorded: S-531011, Pembrolizumab and Bevacizumab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05101070","url":"https://clinicaltrials.gov/study/NCT05101070"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","bevacizumab"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05101070","phase":"1/2","setting":"A Phase 1b/2, Multicenter, Open-label Study of S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors","sponsor":"Shionogi","participation":[{"nct":"NCT05101070","source":"https://clinicaltrials.gov/study/NCT05101070","fetchedAt":"2026-10-07T16:53:34.066Z","studySha256":"f429cd5e454de8edd66bc57ce4e5b812330eb886be93e99e9a672d707374d56a","overallStatus":"RECRUITING","lastUpdatePosted":"2026-03-18","leadSponsor":"Shionogi","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":282,"enrolmentType":"ESTIMATED","siteCount":8,"recruitingSiteCount":6,"countries":["Japan","United States"]}],"started":"2022-05-30","startedType":"actual","enrolled":282,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05101070/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}